Expression of c-kit proto-oncogene product in breast cancer tissues

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 169-174

  Eroğlu, Aydan ^a   Sari, Aliye ^a  

^a Numune State Hospital   (Turkey)

Author keywords

Breast cancer; c kit; Fibroadenoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 36249018385     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698036     Document Type: Article

References (27)

1. Yarden Y, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-3351.
2. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cordo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417-1425.
3. Huang E, et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 225-233.
4. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-6143.
5. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998; 30: 459-466.
6. Hirota S, et al. Gain-of function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
7. Tsuura Y, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424: 135-141.
8. Woenckhaus C, Giebel J, Failing K, Fenic I, Dittberner T, Poetsch M. Expression of AP-2α, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J Pathol 2003; 201: 278-287.
9. Lux ML, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795.
10. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992; 52: 713-717.
11. Chui X, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73: 1233-1236.
12. Ko CD, et al. The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis 2003; 20: 593-597.
13. Yared MA, Middleton LP, Bernstam FM, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J 2004; 10: 323-327.
14. Ulivi P, et al. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat 2004; 83: 33-42.
15. Palmu S, Soderstrom KO, Quazi K, Isola J, Salminen E. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 2002; 22: 411-414.
16. Hines SJ, Organ C, Kornstein MJ, Krystal GW. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995; 6: 769-779.
17. Tsuda H, et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with "stem-cell-like" features. Cancer Sci 2005; 96: 333-339.
18. Simon R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10: 178-183.
19. Crisi GM, Marconi SA, Makari-Judson G, Goulart RA. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol 2005; 124: 733-739.
20. Mastropasqua MG, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol 2005; 18: 1277-1282.
21. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology 1987; 8: 138-140.
22. Mauro M, Druker B. STI 571: targeting BCR-ABL as therapy for CML. Oncologist 2001; 6: 233-238.
23. Joensuu H, et al. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001; 344: 1052-1056.
24. Matsuda R, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142: 339-346.
25. Strohmeyer T, et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 1991; 51: 1811-1816.
26. Tsuura Y, Suzuki T, Honma K, Sano M. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status. J Cancer Res Clin Oncol 2002; 128: 239-246.
27. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-193.